MCDA-LFB Assay Developed for Rapid Detection of Legionnaires’ Disease
|
By LabMedica International staff writers Posted on 18 Jan 2022 |
|
Image: Optimized reaction time for Multiple Cross Displacement Amplification (MCDA-LFB) assay to detect Legionella pneumophila. The best sensitivity was seen when the amplification lasted for 35 minutes (Photo courtesy of Zhejiang Provincial People’s Hospital)
Legionella pneumophila is an opportunistic waterborne pathogen of significant public health problems, which can cause serious human respiratory diseases (Legionnaires’ disease). Legionnaires’ disease is characterized by severe lung infection symptoms, including severe pneumonia with a high fatality rate.
Diagnostic methods, including traditional bacterial culture methods, serological testing, urine antigen detection and nucleic acid amplification techniques, have been developed and used to detect Legionnaires’ disease. Multiple cross displacement amplification (MCDA), a novel isothermal nucleic acid amplification technique, has been applied in detecting many bacterial agents.
Respiratory Medicine Specialists at the Zhejiang Provincial People’s Hospital (Hangzhou; People’s Republic of China) developed a MCDA coupled with Nanoparticles-based Lateral Flow Biosensor (MCDA-LFB) for the rapid detection of L. pneumophila. A total of 40 bacterial strains were used in this assay, including 24 strains of L. pneumophila and 16 strains of non-L. pneumophila. The team used traditional bacterial culture method, conventional PCR detection and MCDA-LFB method to test 88 specimens suspected of L. pneumophila. A set of 10 primers based on the L. pneumophila specific mip gene to specifically identify 10 different target sequence regions of L. pneumophila was designed.
The optimal time and temperature for amplification are 57 minutes and 65 °C. The limit of detection (LoD) is 10 fg in pure cultures of L. pneumophila. No cross-reaction was obtained and the specificity of MCDA-LFB assay was 100%. The whole process of the assay, including 20 minutes of DNA preparation, 35 minutes of L. pneumophila-MCDA reaction, and 2 minutes of sensor strip reaction, took a less than 1 hour. Among 88 specimens for clinical evaluation, five (5.68%) samples were L. pneumophila-positive by MCDA-LFB and traditional culture method, while four (4.55%) samples were L. pneumophila-positive by PCR method targeting mip gene. Compared with culture method, the diagnostic accuracy of MCDA-LFB method was higher.
The authors concluded that the L. pneumophila-MCDA-LFB method they successfully developed is a simple, fast, reliable, and sensitive diagnostic tool, which can be widely used for the identification of L. pneumophila in basic and clinical laboratories. The study was published on January 8, 2022 in the journal BMC Microbiology.
Related Links:
Zhejiang Provincial People’s Hospital
Diagnostic methods, including traditional bacterial culture methods, serological testing, urine antigen detection and nucleic acid amplification techniques, have been developed and used to detect Legionnaires’ disease. Multiple cross displacement amplification (MCDA), a novel isothermal nucleic acid amplification technique, has been applied in detecting many bacterial agents.
Respiratory Medicine Specialists at the Zhejiang Provincial People’s Hospital (Hangzhou; People’s Republic of China) developed a MCDA coupled with Nanoparticles-based Lateral Flow Biosensor (MCDA-LFB) for the rapid detection of L. pneumophila. A total of 40 bacterial strains were used in this assay, including 24 strains of L. pneumophila and 16 strains of non-L. pneumophila. The team used traditional bacterial culture method, conventional PCR detection and MCDA-LFB method to test 88 specimens suspected of L. pneumophila. A set of 10 primers based on the L. pneumophila specific mip gene to specifically identify 10 different target sequence regions of L. pneumophila was designed.
The optimal time and temperature for amplification are 57 minutes and 65 °C. The limit of detection (LoD) is 10 fg in pure cultures of L. pneumophila. No cross-reaction was obtained and the specificity of MCDA-LFB assay was 100%. The whole process of the assay, including 20 minutes of DNA preparation, 35 minutes of L. pneumophila-MCDA reaction, and 2 minutes of sensor strip reaction, took a less than 1 hour. Among 88 specimens for clinical evaluation, five (5.68%) samples were L. pneumophila-positive by MCDA-LFB and traditional culture method, while four (4.55%) samples were L. pneumophila-positive by PCR method targeting mip gene. Compared with culture method, the diagnostic accuracy of MCDA-LFB method was higher.
The authors concluded that the L. pneumophila-MCDA-LFB method they successfully developed is a simple, fast, reliable, and sensitive diagnostic tool, which can be widely used for the identification of L. pneumophila in basic and clinical laboratories. The study was published on January 8, 2022 in the journal BMC Microbiology.
Related Links:
Zhejiang Provincial People’s Hospital
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Chagas Disease Test
LIAISON Chagas
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read more
Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
Technology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
